Cadila Healthcare shares jump 1.5%

BL Internet Desk Chennai | Updated on January 09, 2018 Published on November 24, 2017

Shares of Cadila Healthcare gained as much as 1.5% in Friday's trade as Zydus Cadila has received final approval from the US health regulator to market minocycline hydrochloride extended release tablets used to treat acne.

The company has got final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 45 mg, 80 mg, 90 mg, 105 mg and 135 mg, Zydus Cadila said in a BSE filing today.

Following a weak open at Rs 443.20 against the previous close of Rs 443.50, the scrip touched an intraday high of Rs 450.40 and a low of Rs 442.20. In terms of equity volume, 0.5 lakh shares were traded on the BSE.

The company shares ended up by 0.62 per cent at Rs 446.25.

Cadila Healthcare is the listed entity of the Zydus Group.

(With inputs from PTI)

Published on November 24, 2017
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.